{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:13:12Z","timestamp":1771650792851,"version":"3.50.1"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T00:00:00Z","timestamp":1488499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T00:00:00Z","timestamp":1488499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI050875"],"award-info":[{"award-number":["R01AI050875"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40119-017-0087-5","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T08:39:54Z","timestamp":1488530394000},"page":"13-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Management of Hypertension Using Olmesartan Alone or in Combination"],"prefix":"10.1007","volume":"6","author":[{"given":"Xiaoshen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenliang","family":"Che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6431-4605","authenticated-orcid":false,"given":"Michael R.","family":"Hamblin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,3]]},"reference":[{"issue":"9995","key":"87_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0140-6736(14)61468-9","volume":"386","author":"NR Poulter","year":"2015","unstructured":"Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 2015;386(9995):801\u201312.","journal-title":"Lancet"},{"issue":"9859","key":"87_CR2","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","volume":"380","author":"SS Lim","year":"2012","unstructured":"Lim SS, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224\u201360.","journal-title":"Lancet"},{"key":"87_CR3","doi-asserted-by":"crossref","unstructured":"Collaborators, G.B.D.R.F., et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386(10010):2287\u2013323.","DOI":"10.1016\/S0140-6736(15)00128-2"},{"issue":"9455","key":"87_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(05)70151-3","volume":"365","author":"PM Kearney","year":"2005","unstructured":"Kearney PM, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217\u201323.","journal-title":"Lancet"},{"issue":"1","key":"87_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/01.HYP.0000252676.46043.18","volume":"49","author":"KL Ong","year":"2007","unstructured":"Ong KL, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999\u20132004. Hypertension. 2007;49(1):69\u201375.","journal-title":"Hypertension"},{"issue":"18","key":"87_CR6","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1001\/jama.289.18.2363","volume":"289","author":"K Wolf-Maier","year":"2003","unstructured":"Wolf-Maier K, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289(18):2363\u20139.","journal-title":"JAMA"},{"issue":"9","key":"87_CR7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2165\/00003495-200868090-00003","volume":"68","author":"DH Smith","year":"2008","unstructured":"Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9):1207\u201325.","journal-title":"Drugs"},{"key":"87_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/VHRM.S16852","volume":"7","author":"R Kreutz","year":"2011","unstructured":"Kreutz R. Olmesartan\/amlodipine: a review of its use in the management of hypertension. Vasc Health Risk Manag. 2011;7:183\u201392.","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"87_CR9","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206\u201352.","journal-title":"Hypertension"},{"key":"87_CR10","doi-asserted-by":"crossref","unstructured":"Safar ME, Struijker-Boudier HA. New goals in hypertension management: target-organ protection beyond blood pressure lowering. Drugs 2003;63(Spec No 1):45\u20137.","DOI":"10.2165\/00003495-200363991-00006"},{"key":"87_CR11","first-page":"1","volume":"11","author":"P Bramlage","year":"2015","unstructured":"Bramlage P, et al. Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice. Vasc Health Risk Manag. 2015;11:1\u20138.","journal-title":"Vasc Health Risk Manag"},{"issue":"19","key":"87_CR12","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560\u201372.","journal-title":"JAMA"},{"issue":"12","key":"87_CR13","first-page":"1462","volume":"28","author":"G Mancia","year":"2007","unstructured":"Mancia G, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462\u2013536.","journal-title":"Eur Heart J"},{"issue":"1","key":"87_CR14","first-page":"3","volume":"32","author":"T Ogihara","year":"2009","unstructured":"Ogihara T, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009;32(1):3\u2013107.","journal-title":"Hypertens Res"},{"issue":"4","key":"87_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1161\/01.HYP.1.4.384","volume":"1","author":"LS Marks","year":"1979","unstructured":"Marks LS, Maxwell MH. Tigerstedt and the discovery of renin. An historical note. Hypertension. 1979;1(4):384\u20138.","journal-title":"Hypertension"},{"issue":"9","key":"87_CR16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1084\/jem.2019fta","volume":"201","author":"HL Van Epps","year":"2005","unstructured":"Van Epps HL. Harry Goldblatt and the discovery of renin. J Exp Med. 2005;201(9):1351.","journal-title":"J Exp Med"},{"issue":"9204","key":"87_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","volume":"355","author":"M Burnier","year":"2000","unstructured":"Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355(9204):637\u201345.","journal-title":"Lancet"},{"issue":"2","key":"87_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.nec.2009.10.011","volume":"21","author":"AH Yee","year":"2010","unstructured":"Yee AH, Burns JD, Wijdicks EF. Cerebral salt wasting: pathophysiology, diagnosis, and treatment. Neurosurg Clin N Am. 2010;21(2):339\u201352.","journal-title":"Neurosurg Clin N Am"},{"issue":"8","key":"87_CR19","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/archinte.1985.00360080153023","volume":"145","author":"IA Reid","year":"1985","unstructured":"Reid IA. The renin\u2013angiotensin system and body function. Arch Intern Med. 1985;145(8):1475\u20139.","journal-title":"Arch Intern Med"},{"key":"87_CR20","doi-asserted-by":"crossref","unstructured":"Unger T. The role of the renin\u2013angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89(2, Supplement 1):3\u20139.","DOI":"10.1016\/S0002-9149(01)02321-9"},{"issue":"3","key":"87_CR21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1152\/physrev.00036.2005","volume":"86","author":"M Paul","year":"2006","unstructured":"Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin\u2013angiotensin systems. Physiol Rev. 2006;86(3):747\u2013803.","journal-title":"Physiol Rev"},{"issue":"8","key":"87_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1096\/fj.03-0093life","volume":"17","author":"CG Smith","year":"2003","unstructured":"Smith CG, Vane JR. The discovery of captopril. FASEB J. 2003;17(8):788\u20139.","journal-title":"FASEB J"},{"issue":"10","key":"87_CR23","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1021\/ml500278g","volume":"5","author":"MO Guimond","year":"2014","unstructured":"Guimond MO, et al. Saralasin and sarile are AT2 receptor agonists. ACS Med Chem Lett. 2014;5(10):1129\u201332.","journal-title":"ACS Med Chem Lett"},{"issue":"2\u20135","key":"87_CR24","first-page":"295","volume":"27","author":"PB Timmermans","year":"1990","unstructured":"Timmermans PB, et al. Nonpeptide angiotensin II receptor antagonists: a novel class of antihypertensive agents. Blood Vessels. 1990;27(2\u20135):295\u2013300.","journal-title":"Blood Vessels"},{"issue":"2","key":"87_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1124\/pr.112.007278","volume":"65","author":"MC Michel","year":"2013","unstructured":"Michel MC, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013;65(2):809\u201348.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"87_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1124\/dmd.111.041475","volume":"40","author":"T Ishizuka","year":"2012","unstructured":"Ishizuka T, et al. Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism. Drug Metab Dispos. 2012;40(2):374\u201380.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"87_CR27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/01.CIR.0000137118.47943.5C","volume":"110","author":"MM Ciulla","year":"2004","unstructured":"Ciulla MM, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation. 2004;110(5):552\u20137.","journal-title":"Circulation"},{"issue":"5","key":"87_CR28","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.clinthera.2005.05.006","volume":"27","author":"LM Ruilope","year":"2005","unstructured":"Ruilope LM, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005;27(5):578\u201387.","journal-title":"Clin Ther"},{"issue":"2","key":"87_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1136\/eb-2012-100851","volume":"18","author":"FD Fuchs","year":"2013","unstructured":"Fuchs FD. The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment? Evid Based Med. 2013;18(2):44\u20137.","journal-title":"Evid Based Med"},{"issue":"5","key":"87_CR30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","volume":"21","author":"H Lithell","year":"2003","unstructured":"Lithell H, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875\u201386.","journal-title":"J Hypertens"},{"issue":"9644","key":"87_CR31","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","volume":"372","author":"Telmisartan Randomised AssessmeNt Study in A.C.E.i.s.w.c.D.I.","year":"2008","unstructured":"Telmisartan Randomised AssessmeNt Study in A.C.E.i.s.w.c.D.I., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174\u201383.","journal-title":"Lancet"},{"issue":"12","key":"87_CR32","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","volume":"359","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359(12):1225\u201337.","journal-title":"N Engl J Med"},{"key":"87_CR33","doi-asserted-by":"crossref","unstructured":"NS Group, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010. 362(16):1477\u201390.","DOI":"10.1056\/NEJMoa1001121"},{"issue":"12","key":"87_CR34","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","volume":"54","author":"E Imai","year":"2011","unstructured":"Imai E, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54(12):2978\u201386.","journal-title":"Diabetologia"},{"issue":"1","key":"87_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1056\/NEJMoa0808400","volume":"361","author":"M Mauer","year":"2009","unstructured":"Mauer M, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361(1):40\u201351.","journal-title":"N Engl J Med"},{"issue":"15","key":"87_CR36","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"O Investigators","year":"2008","unstructured":"Investigators O, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547\u201359.","journal-title":"N Engl J Med"},{"issue":"1","key":"87_CR37","doi-asserted-by":"publisher","first-page":"e000236","DOI":"10.1136\/openhrt-2014-000236","volume":"2","author":"FD Fuchs","year":"2015","unstructured":"Fuchs FD, DiNicolantonio JJ. Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand? Open Heart. 2015;2(1):e000236.","journal-title":"Open Heart"},{"key":"87_CR38","doi-asserted-by":"publisher","first-page":"d2234","DOI":"10.1136\/bmj.d2234","volume":"342","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147,020 patients from randomised trials. BMJ. 2011;342:d2234.","journal-title":"BMJ"},{"issue":"16","key":"87_CR39","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","volume":"33","author":"LC van Vark","year":"2012","unstructured":"van Vark LC, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin\u2013angiotensin\u2013aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088\u201397.","journal-title":"Eur Heart J"},{"issue":"5","key":"87_CR40","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","volume":"174","author":"J Cheng","year":"2014","unstructured":"Cheng J, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174(5):773\u201385.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"87_CR41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/ajh\/hpu209","volume":"28","author":"IY Elgendy","year":"2015","unstructured":"Elgendy IY, et al. Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials. Am J Hypertens. 2015;28(5):576\u201385.","journal-title":"Am J Hypertens"},{"key":"87_CR42","unstructured":"Benicar HCT prescribing information. Revised 07\/2013. Daiichi Sankyo, Inc. Reference ID: 3335147. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021532s022lbl.pdf . Accessed June 26, 2016."},{"issue":"1","key":"87_CR43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.109.131300","volume":"54","author":"DA Calhoun","year":"2009","unstructured":"Calhoun DA, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54(1):32\u20139.","journal-title":"Hypertension"},{"issue":"1","key":"87_CR44","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/00004872-200106001-00004","volume":"19","author":"P Laeis","year":"2001","unstructured":"Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl. 2001;19(1):S21\u201332.","journal-title":"J Hypertens Suppl"},{"issue":"9","key":"87_CR45","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2165\/00003495-200868090-00005","volume":"68","author":"LJ Scott","year":"2008","unstructured":"Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008;68(9):1239\u201372.","journal-title":"Drugs"},{"issue":"12","key":"87_CR46","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1124\/dmd.105.006163","volume":"33","author":"SF Ma","year":"2005","unstructured":"Ma SF, et al. Hydrolysis of angiotensin II receptor blocker prodrug olmesartan medoxomil by human serum albumin and identification of its catalytic active sites. Drug Metab Dispos. 2005;33(12):1911\u20139.","journal-title":"Drug Metab Dispos"},{"key":"87_CR47","unstructured":"Daiichi Sankyo UK Limited. Olmetec plus film-coated tablets 20\u00a0mg\/12.5\u00a0mg and 20\u00a0mg\/25\u00a0mg; summary of product characteristics. http:\/\/emc.medicines.org.uk ; information for the user, http:\/\/www.medicines.org.uk\/emc\/PIL.17689.latest.pdf . Accessed June 26, 2016."},{"key":"87_CR48","unstructured":"Novartis. Diovan-HCT prescribing information. https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/diovan_hct.pdf . Accessed June 26, 2016."},{"issue":"4","key":"87_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2165\/00129784-200909040-00001","volume":"9","author":"SG Chrysant","year":"2009","unstructured":"Chrysant SG, Chavanu KJ, Xu J. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. Am J Cardiovasc Drugs. 2009;9(4):241\u201351.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"87_CR50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.amjhyper.2003.11.003","volume":"17","author":"SG Chrysant","year":"2004","unstructured":"Chrysant SG, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17(3):252\u20139.","journal-title":"Am J Hypertens"},{"issue":"3","key":"87_CR51","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ihj.2014.05.002","volume":"66","author":"DK Kumbla","year":"2014","unstructured":"Kumbla DK, et al. WIN OVER study: efficacy and safety of olmesartan in Indian hypertensive patients: results of an open-label, non-comparative, multi-centric, post marketing observational study. Indian Heart J. 2014;66(3):340\u20134.","journal-title":"Indian Heart J"},{"issue":"7","key":"87_CR52","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1185\/030079906X115630","volume":"22","author":"M Bohm","year":"2006","unstructured":"Bohm M, Ewald S, Olmebest Study A. Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open-label sub-study in German patients. Curr Med Res Opin. 2006;22(7):1375\u201380.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"87_CR53","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00044011-200323070-00001","volume":"23","author":"HR Brunner","year":"2003","unstructured":"Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Investig. 2003;23(7):419\u201330.","journal-title":"Clin Drug Investig"},{"key":"87_CR54","unstructured":"Oparil S, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(5):283\u201391, 318."},{"issue":"1","key":"87_CR55","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00129784-200505010-00006","volume":"5","author":"DH Smith","year":"2005","unstructured":"Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5(1):41\u201350.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"87_CR56","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jash.2011.09.003","volume":"6","author":"SG Chrysant","year":"2012","unstructured":"Chrysant SG, et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J Am Soc Hypertens. 2012;6(2):132\u201341.","journal-title":"J Am Soc Hypertens"},{"issue":"3","key":"87_CR57","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/01.mbp.0000209087.40117.b3","volume":"11","author":"SG Chrysant","year":"2006","unstructured":"Chrysant SG, Marbury TC, Silfani TN. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monit. 2006;11(3):135\u201341.","journal-title":"Blood Press Monit"},{"issue":"12","key":"87_CR58","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s40266-012-0030-3","volume":"29","author":"S Omboni","year":"2012","unstructured":"Omboni S, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild-to-moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials. Drugs Aging. 2012;29(12):981\u201392.","journal-title":"Drugs Aging"},{"issue":"Suppl 2","key":"87_CR59","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/sj.jhh.1001395","volume":"16","author":"KO Stumpe","year":"2002","unstructured":"Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens. 2002;16(Suppl 2):S24\u20138.","journal-title":"J Hum Hypertens"},{"issue":"5","key":"87_CR60","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/BF03261842","volume":"12","author":"L Wang","year":"2012","unstructured":"Wang L, et al. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis. Am J Cardiovasc Drugs. 2012;12(5):335\u201344.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"11","key":"87_CR61","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/jhh.2010.5","volume":"24","author":"SG Chrysant","year":"2010","unstructured":"Chrysant SG, et al. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens. 2010;24(11):730\u20138.","journal-title":"J Hum Hypertens"},{"issue":"4","key":"87_CR62","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.clinthera.2008.04.002","volume":"30","author":"SG Chrysant","year":"2008","unstructured":"Chrysant SG, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587\u2013604.","journal-title":"Clin Ther"},{"issue":"1","key":"87_CR63","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s10753-013-9724-x","volume":"37","author":"G Derosa","year":"2014","unstructured":"Derosa G, et al. Different aspects of sartan\u00a0+\u00a0calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. Inflammation. 2014;37(1):154\u201362.","journal-title":"Inflammation"},{"issue":"1","key":"87_CR64","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/jcpt.12021","volume":"38","author":"G Derosa","year":"2013","unstructured":"Derosa G, et al. Effects of an olmesartan\/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies. J Clin Pharm Ther. 2013;38(1):48\u201355.","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"87_CR65","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3109\/10641963.2012.721841","volume":"35","author":"G Derosa","year":"2013","unstructured":"Derosa G, et al. Olmesartan\/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. Clin Exp Hypertens. 2013;35(5):301\u20137.","journal-title":"Clin Exp Hypertens"},{"key":"87_CR66","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejps.2013.08.031","volume":"51","author":"G Derosa","year":"2014","unstructured":"Derosa G, et al. Results from a 12\u00a0months, randomized, clinical trial comparing an olmesartan\/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur J Pharm Sci. 2014;51:26\u201333.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"87_CR67","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jash.2012.11.006","volume":"7","author":"G Derosa","year":"2013","unstructured":"Derosa G, et al. Variation of some inflammatory markers in hypertensive patients after 1\u00a0year of olmesartan\/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. J Am Soc Hypertens. 2013;7(1):32\u20139.","journal-title":"J Am Soc Hypertens"},{"key":"87_CR68","first-page":"3935","volume":"9","author":"P Sievers","year":"2015","unstructured":"Sievers P, et al. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis. Drug Des Devel Ther. 2015;9:3935\u201342.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"87_CR69","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1161\/HYPERTENSIONAHA.107.090068","volume":"50","author":"E Agabiti-Rosei","year":"2007","unstructured":"Agabiti-Rosei E, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50(1):154\u201360.","journal-title":"Hypertension"},{"issue":"4","key":"87_CR70","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/HYPERTENSIONAHA.109.131466","volume":"54","author":"Y Matsui","year":"2009","unstructured":"Matsui Y, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension. 2009;54(4):716\u201323.","journal-title":"Hypertension"},{"issue":"4","key":"87_CR71","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/1479164112447310","volume":"9","author":"H Daikuhara","year":"2012","unstructured":"Daikuhara H, Kikuchi F, Ishida T. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study. Diab Vasc Dis Res. 2012;9(4):280\u20136.","journal-title":"Diab Vasc Dis Res"},{"issue":"1","key":"87_CR72","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1185\/03007995.2011.637914","volume":"28","author":"C Axthelm","year":"2012","unstructured":"Axthelm C, et al. Efficacy and tolerability of the single-pill combination of aliskiren 300\u00a0mg\/amlodipine 10\u00a0mg in hypertensive patients not controlled by olmesartan 40\u00a0mg\/amlodipine 10\u00a0mg. Curr Med Res Opin. 2012;28(1):69\u201378.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"87_CR73","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1007\/s12325-013-0076-6","volume":"30","author":"L Ruilope","year":"2013","unstructured":"Ruilope L, Schaefer A. The fixed-dose combination of olmesartan\/amlodipine was superior in central aortic blood pressure reduction compared with perindopril\/amlodipine: a randomized, double-blind trial in patients with hypertension. Adv Ther. 2013;30(12):1086\u201399.","journal-title":"Adv Ther"},{"issue":"6","key":"87_CR74","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/jch.12673","volume":"18","author":"LM Ruilope","year":"2016","unstructured":"Ruilope LM, Investigators SS. Fixed-combination olmesartan\/amlodipine was superior to perindopril\u00a0+\u00a0amlodipine in reducing central systolic blood pressure in hypertensive patients with diabetes. J Clin Hypertens (Greenwich). 2016;18(6):528\u201335.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"7","key":"87_CR75","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.clinthera.2010.07.008","volume":"32","author":"S Oparil","year":"2010","unstructured":"Oparil S, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7):1252\u201369.","journal-title":"Clin Ther"},{"issue":"2","key":"87_CR76","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jash.2010.03.003","volume":"4","author":"TG Pickering","year":"2010","unstructured":"Pickering TG, et al. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens. 2010;4(2):56\u201361.","journal-title":"J Am Soc Hypertens"},{"key":"87_CR77","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1475-2840-11-134","volume":"11","author":"DJ Kereiakes","year":"2012","unstructured":"Kereiakes DJ, et al. Olmesartan\/amlodipine\/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovasc Diabetol. 2012;11:134.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"87_CR78","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/jch.12133","volume":"15","author":"EM Roth","year":"2013","unstructured":"Roth EM, et al. Olmesartan\/amlodipine\/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis. J Clin Hypertens (Greenwich). 2013;15(8):584\u201392.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"87_CR79","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/BF03261832","volume":"12","author":"SG Chrysant","year":"2012","unstructured":"Chrysant SG, et al. Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study. Am J Cardiovasc Drugs. 2012;12(4):233\u201343.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"15","key":"87_CR80","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/eurheartj\/ehu504","volume":"36","author":"Y Sakata","year":"2015","unstructured":"Sakata Y, et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J. 2015;36(15):915\u201323.","journal-title":"Eur Heart J"},{"issue":"6","key":"87_CR81","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3109\/10641963.2015.1013119","volume":"37","author":"HW Jung","year":"2015","unstructured":"Jung HW, et al. A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan\/amlodipine in Korean patients with hypertension who are naive or non-responders to anti-hypertensive monotherapy (ACE-HY study). Clin Exp Hypertens. 2015;37(6):482\u20139.","journal-title":"Clin Exp Hypertens"},{"key":"87_CR82","doi-asserted-by":"crossref","unstructured":"Mohan JC, et al. Short term safety and tolerability of a fixed dose combination of olmesartan, amlodipine and hydrochlorothiazide. J Clin Diagn Res. 2015;9(8):OC10\u20133.","DOI":"10.7860\/JCDR\/2015\/14054.6366"},{"issue":"8A","key":"87_CR83","doi-asserted-by":"publisher","first-page":"37C","DOI":"10.1016\/S0002-9149(01)01510-7","volume":"87","author":"JM Neutel","year":"2001","unstructured":"Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol. 2001;87(8A):37C\u201343C.","journal-title":"Am J Cardiol"},{"issue":"1","key":"87_CR84","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/00004872-200106001-00007","volume":"19","author":"KJ Ball","year":"2001","unstructured":"Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens Suppl. 2001;19(1):S49\u201356.","journal-title":"J Hypertens Suppl"},{"key":"87_CR85","unstructured":"Benicar HCT prescribing information. Revised 07\/2013. Daiichi Sankyo, I.R.I.A.f.U.h.w.a.f.g.d.d.l.s.l.p. and A.S. 23."},{"issue":"1","key":"87_CR86","first-page":"131","volume":"30","author":"M Galanopoulos","year":"2017","unstructured":"Galanopoulos M, et al. Small bowel enteropathy associated with olmesartan medoxomil treatment. Ann Gastroenterol. 2017;30(1):131\u20133.","journal-title":"Ann Gastroenterol"},{"issue":"24","key":"87_CR87","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.2169\/internalmedicine.55.7388","volume":"55","author":"T Uehara","year":"2016","unstructured":"Uehara T, et al. Olmesartan-induced enteropathy manifesting as Wernicke\u2013Korsakoff syndrome. Intern Med. 2016;55(24):3675\u20138.","journal-title":"Intern Med"},{"key":"87_CR88","doi-asserted-by":"publisher","first-page":"6091571","DOI":"10.1155\/2016\/6091571","volume":"2016","author":"T Kulai","year":"2016","unstructured":"Kulai T, et al. Duodenal villous atrophy in a TTG-negative patient taking olmesartan: a case report and review of the literature. Can J Gastroenterol Hepatol. 2016;2016:6091571.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"4","key":"87_CR89","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ccr3.531","volume":"4","author":"N Hammoudi","year":"2016","unstructured":"Hammoudi N, et al. Olmesartan-induced enteropathy associated with cutaneous lesions. Clin Case Rep. 2016;4(4):379\u201382.","journal-title":"Clin Case Rep"},{"key":"87_CR90","doi-asserted-by":"publisher","first-page":"4837270","DOI":"10.1155\/2016\/4837270","volume":"2016","author":"C Desruisseaux","year":"2016","unstructured":"Desruisseaux C, et al. Adding water to the mill: olmesartan-induced collagenous sprue\u2014a case report and brief literature review. Can J Gastroenterol Hepatol. 2016;2016:4837270.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"8","key":"87_CR91","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.mayocp.2012.06.003","volume":"87","author":"A Rubio-Tapia","year":"2012","unstructured":"Rubio-Tapia A, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87(8):732\u20138.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"87_CR92","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/ajg.2013.45","volume":"108","author":"M DeGaetani","year":"2013","unstructured":"DeGaetani M, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108(5):647\u201353.","journal-title":"Am J Gastroenterol"},{"key":"87_CR93","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.humpath.2015.12.001","volume":"50","author":"N Burbure","year":"2016","unstructured":"Burbure N, et al. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127\u201334.","journal-title":"Hum Pathol"},{"issue":"11\u201312","key":"87_CR94","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/apt.13413","volume":"42","author":"EV Marietta","year":"2015","unstructured":"Marietta EV, et al. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther. 2015;42(11\u201312):1303\u201314.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"87_CR95","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/apt.12780","volume":"40","author":"G Ianiro","year":"2014","unstructured":"Ianiro G, et al. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40(1):16\u201323.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11\u201312","key":"87_CR96","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/apt.13000","volume":"40","author":"A Rubio-Tapia","year":"2014","unstructured":"Rubio-Tapia A. Sprue-like enteropathy associated with olmesartan\u2014broadening the differential diagnosis of enteropathy. Aliment Pharmacol Ther. 2014;40(11\u201312):1362\u20133.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"87_CR97","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/apt.12937","volume":"40","author":"L Marthey","year":"2014","unstructured":"Marthey L, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014;40(9):1103\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"87_CR98","unstructured":"FDA Drug Safety Communication. FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine. olmesartan medoxomil. http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM359496.pdf . Accessed Feb 6, 2017."},{"issue":"2","key":"87_CR99","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijcard.2009.09.543","volume":"141","author":"JF Thayer","year":"2010","unstructured":"Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 2010;141(2):122\u201331.","journal-title":"Int J Cardiol"},{"issue":"2","key":"87_CR100","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/hr.2014.141","volume":"38","author":"T Saruta","year":"2015","unstructured":"Saruta T, et al. Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability. Hypertens Res. 2015;38(2):132\u20136.","journal-title":"Hypertens Res"},{"key":"87_CR101","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/bs.podrm.2015.02.003","volume":"40","author":"AR Al-Majed","year":"2015","unstructured":"Al-Majed AR, et al. Losartan: comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2015;40:159\u201394.","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"7","key":"87_CR102","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.clinthera.2005.07.010","volume":"27","author":"Y Lacourciere","year":"2005","unstructured":"Lacourciere Y, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther. 2005;27(7):1013\u201321.","journal-title":"Clin Ther"},{"issue":"4","key":"87_CR103","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1527-3466.2004.tb00146.x","volume":"22","author":"CH Gleiter","year":"2004","unstructured":"Gleiter CH, et al. Candesartan. Cardiovasc Drug Rev. 2004;22(4):263\u201384.","journal-title":"Cardiovasc Drug Rev"},{"issue":"12 Pt 2","key":"87_CR104","doi-asserted-by":"publisher","first-page":"311S","DOI":"10.1016\/S0895-7061(97)00391-9","volume":"10","author":"HR Brunner","year":"1997","unstructured":"Brunner HR. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens. 1997;10(12 Pt 2):311S\u20137S.","journal-title":"Am J Hypertens"},{"issue":"4","key":"87_CR105","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.jhh.1002293","volume":"22","author":"JM Neutel","year":"2008","unstructured":"Neutel JM, et al. A comparison of the efficacy and safety of irbesartan\/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens. 2008;22(4):266\u201374.","journal-title":"J Hum Hypertens"},{"issue":"4 Pt 2","key":"87_CR106","doi-asserted-by":"publisher","first-page":"73S","DOI":"10.1592\/phco.19.7.73S.30946","volume":"19","author":"MB Bottorff","year":"1999","unstructured":"Bottorff MB, Tenero DM. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy. 1999;19(4 Pt 2):73S\u20138S.","journal-title":"Pharmacotherapy"},{"issue":"4 Pt 2","key":"87_CR107","doi-asserted-by":"publisher","first-page":"102S","DOI":"10.1592\/phco.19.7.102S.30945","volume":"19","author":"I Gavras","year":"1999","unstructured":"Gavras I, Gavras H. Safety and tolerability of eprosartan. Pharmacotherapy. 1999;19(4 Pt 2):102S\u20137S.","journal-title":"Pharmacotherapy"},{"key":"87_CR108","unstructured":"Chopra A. Molecular imaging and contrast agent database (MICAD), In: 11C-labeled telmisartan, an angiotensin II type 1 receptor antagonist. MD: National Center for Biotechnology Information, NLM, Bethesda; 2004."},{"issue":"6","key":"87_CR109","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1751-7176.2010.00287.x","volume":"12","author":"Z Zheng","year":"2010","unstructured":"Zheng Z, Lin S, Shi H. A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension. J Clin Hypertens (Greenwich). 2010;12(6):414\u201321.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"87_CR110","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1345\/aph.1C197","volume":"37","author":"SF Gardner","year":"2003","unstructured":"Gardner SF, Franks AM. Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann Pharmacother. 2003;37(1):99\u2013105.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"87_CR111","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/01.fjc.0000180902.78230.fd","volume":"46","author":"DE Mire","year":"2005","unstructured":"Mire DE, Silfani TN, Pugsley MK. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2005;46(5):585\u201393.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"87_CR112","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40256-013-0004-9","volume":"13","author":"JB Park","year":"2013","unstructured":"Park JB, et al. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study. Am J Cardiovasc Drugs. 2013;13(1):47\u201356.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"87_CR113","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/jcph.618","volume":"56","author":"JL Ghim","year":"2016","unstructured":"Ghim JL, et al. Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects. J Clin Pharmacol. 2016;56(5):576\u201380.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"87_CR114","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.clinthera.2011.10.007","volume":"33","author":"K Zaiken","year":"2011","unstructured":"Zaiken K, Cheng JW. Azilsartan medoxomil: a new angiotensin receptor blocker. Clin Ther. 2011;33(11):1577\u201389.","journal-title":"Clin Ther"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-017-0087-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40119-017-0087-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-017-0087-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T23:44:31Z","timestamp":1750031071000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40119-017-0087-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,3]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["87"],"URL":"https:\/\/doi.org\/10.1007\/s40119-017-0087-5","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,3]]},"assertion":[{"value":"17 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}